These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 32397775)

  • 1. In Ataxia-Telangiectasia, Oral Betamethasone Administration Ameliorates Lymphocytes Functionality through Modulation of the IL-7/IL-7Rα Axis Paralleling the Neurological Behavior: A Comparative Report of Two Cases.
    Prencipe R; Cirillo E; Giardino G; Gallo V; Menotta M; Magnani M; Barone MV; Palamaro L; Scalia G; Del Vecchio L; Pignata C
    Immunol Invest; 2021 Feb; 50(2-3):295-303. PubMed ID: 32397775
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Minimum effective betamethasone dosage on the neurological phenotype in patients with ataxia-telangiectasia: a multicenter observer-blind study.
    Cirillo E; Del Giudice E; Micheli R; Cappellari AM; Soresina A; Dellepiane RM; Pietrogrande MC; Dell'Era L; Specchia F; Pession A; Plebani A; Pignata C
    Eur J Neurol; 2018 Jun; 25(6):833-840. PubMed ID: 29489040
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In ataxia-teleangiectasia betamethasone response is inversely correlated to cerebellar atrophy and directly to antioxidative capacity.
    Russo I; Cosentino C; Del Giudice E; Broccoletti T; Amorosi S; Cirillo E; Aloj G; Fusco A; Costanzo V; Pignata C
    Eur J Neurol; 2009 Jun; 16(6):755-9. PubMed ID: 19475758
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-Term Evaluation of Low-Dose Betamethasone for Ataxia Telangiectasia.
    Hasegawa S; Kumada S; Tanuma N; Tsuji-Hosokawa A; Kashimada A; Mizuno T; Moriyama K; Sugawara Y; Shirai I; Miyata Y; Nishida H; Mashimo H; Hasegawa T; Hosokawa T; Hisakawa H; Uematsu M; Fujine A; Miyata R; Sakuma H; Kashimada K; Imai K; Morio T; Hayashi M; Mizutani S; Takagi M
    Pediatr Neurol; 2019 Nov; 100():60-66. PubMed ID: 31272782
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of very-low-dose betamethasone on neurological symptoms in ataxia-telangiectasia.
    Broccoletti T; Del Giudice E; Cirillo E; Vigliano I; Giardino G; Ginocchio VM; Bruscoli S; Riccardi C; Pignata C
    Eur J Neurol; 2011 Apr; 18(4):564-70. PubMed ID: 20840352
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Suppressor of cytokine signalling 3 is crucial for interleukin-7 receptor re-expression after T-cell activation and interleukin-7 dependent proliferation.
    Güler A; Lopez Venegas M; Adankwah E; Mayatepek E; Nausch N; Jacobsen M
    Eur J Immunol; 2020 Feb; 50(2):234-244. PubMed ID: 31621896
    [TBL] [Abstract][Full Text] [Related]  

  • 7. IL-7 induces rapid clathrin-mediated internalization and JAK3-dependent degradation of IL-7Ralpha in T cells.
    Henriques CM; Rino J; Nibbs RJ; Graham GJ; Barata JT
    Blood; 2010 Apr; 115(16):3269-77. PubMed ID: 20190194
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Steroid-induced improvement of neurological signs in ataxia-telangiectasia patients.
    Broccoletti T; Del Giudice E; Amorosi S; Russo I; Di Bonito M; Imperati F; Romano A; Pignata C
    Eur J Neurol; 2008 Mar; 15(3):223-8. PubMed ID: 18290844
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Steroid treatment in Ataxia-Telangiectasia induces alterations of functional magnetic resonance imaging during prono-supination task.
    Quarantelli M; Giardino G; Prinster A; Aloj G; Carotenuto B; Cirillo E; Marsili A; Salvatore E; Del Giudice E; Pignata C
    Eur J Paediatr Neurol; 2013 Mar; 17(2):135-40. PubMed ID: 22763152
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential regulation of human IL-7 receptor alpha expression by IL-7 and TCR signaling.
    Alves NL; van Leeuwen EM; Derks IA; van Lier RA
    J Immunol; 2008 Apr; 180(8):5201-10. PubMed ID: 18390701
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Betamethasone therapy in ataxia telangiectasia: unraveling the rationale of this serendipitous observation on the basis of the pathogenesis.
    Giardino G; Fusco A; Romano R; Gallo V; Maio F; Esposito T; Palamaro L; Parenti G; Salerno MC; Vajro P; Pignata C
    Eur J Neurol; 2013 May; 20(5):740-7. PubMed ID: 23121321
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Elevated expression of interleukin-7 receptor in inflamed joints mediates interleukin-7-induced immune activation in rheumatoid arthritis.
    Hartgring SA; van Roon JA; Wenting-van Wijk M; Jacobs KM; Jahangier ZN; Willis CR; Bijlsma JW; Lafeber FP
    Arthritis Rheum; 2009 Sep; 60(9):2595-605. PubMed ID: 19714586
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized trial of oral betamethasone to reduce ataxia symptoms in ataxia telangiectasia.
    Zannolli R; Buoni S; Betti G; Salvucci S; Plebani A; Soresina A; Pietrogrande MC; Martino S; Leuzzi V; Finocchi A; Micheli R; Rossi LN; Brusco A; Misiani F; Fois A; Hayek J; Kelly C; Chessa L
    Mov Disord; 2012 Sep; 27(10):1312-6. PubMed ID: 22927201
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased interleukin (IL)-7Rα expression in salivary glands of patients with primary Sjogren's syndrome is restricted to T cells and correlates with IL-7 expression, lymphocyte numbers and activity.
    Bikker A; Kruize AA; Wenting M; Versnel MA; Bijlsma JW; Lafeber FP; van Roon JA
    Ann Rheum Dis; 2012 Jun; 71(6):1027-33. PubMed ID: 22312161
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Betamethasone and improvement of neurological symptoms in ataxia-telangiectasia.
    Buoni S; Zannolli R; Sorrentino L; Fois A
    Arch Neurol; 2006 Oct; 63(10):1479-82. PubMed ID: 17030666
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The IL-7Rα pathway is quantitatively and functionally altered in CD8 T cells in multiple sclerosis.
    Kreft KL; Verbraak E; Wierenga-Wolf AF; van Meurs M; Oostra BA; Laman JD; Hintzen RQ
    J Immunol; 2012 Feb; 188(4):1874-83. PubMed ID: 22262655
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A fully human anti-IL-7Rα antibody promotes antitumor activity against T-cell acute lymphoblastic leukemia.
    Akkapeddi P; Fragoso R; Hixon JA; Ramalho AS; Oliveira ML; Carvalho T; Gloger A; Matasci M; Corzana F; Durum SK; Neri D; Bernardes GJL; Barata JT
    Leukemia; 2019 Sep; 33(9):2155-2168. PubMed ID: 30850736
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interleukin-7 compartmentalizes its receptor signaling complex to initiate CD4 T lymphocyte response.
    Rose T; Pillet AH; Lavergne V; Tamarit B; Lenormand P; Rousselle JC; Namane A; Thèze J
    J Biol Chem; 2010 May; 285(20):14898-14908. PubMed ID: 20167604
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Loss of IL-7Ralpha is associated with CD4 T-cell depletion, high interleukin-7 levels and CD28 down-regulation in HIV infected patients.
    Rethi B; Fluur C; Atlas A; Krzyzowska M; Mowafi F; Grützmeier S; De Milito A; Bellocco R; Falk KI; Rajnavölgyi E; Chiodi F
    AIDS; 2005 Dec; 19(18):2077-86. PubMed ID: 16284456
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interferon-
    Henriquez JE; Rizzo MD; Crawford RB; Gulick P; Kaminski NE
    J Pharmacol Exp Ther; 2018 Oct; 367(1):49-58. PubMed ID: 30026298
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.